Howard (Ted) Greene, Jr. is an accomplished entrepreneur and investor in the biotechnology industry. During a business career spanning over three decades, Mr. Greene has gained experience in various aspects of early stage medical technology companies. Both as an inventor and entrepreneur, and as a venture capitalist, he has been involved in starting, funding, and/or managing ten technology-driven enterprises, all of which have gone public.
Prior to his retirement in 1998, Mr. Greene was Chairman of Amylin Pharmaceuticals, Inc., a company he co-founded in 1987 that has launched two first-in-class diabetes drugs. Mr. Greene holds several patents directed to using the hormone amylin in diabetes therapy. Before starting Amylin, Mr. Greene co-founded Biovest Partners, a venture capital firm that in two years provided seed capital and management leadership for six medical technology start-up companies, including Amylin, and that returned about ten-fold its limited partners’ investment in less than five years. All six companies were taken public, and four of them– Pyxis Corporation, Neurex Corporation, Epimmune Inc, and Biosite Incorporated – have been acquired. The other two – Amylin and Vical – remain publicly traded companies.
Prior to Biovest, Mr. Greene was Chief Executive Officer of Hybritech Incorporated, essentially from inception until its acquisition by Eli Lilly and Company in 1986. Before Hybritech, Mr. Greene was an executive with Baxter Healthcare Corporation for five years, and prior to that he was a consultant with McKinsey & Company for seven years. He is presently a director of several early stage startups in the biotech and internet fields. Mr. Greene holds a Masters of Business Administration from Harvard University and a BA in physics from Amherst College.